Eurofins Bioanalytical Services launches Surrogate Virus Neutralizing antibody detection assays against the SARS-CoV-2 (COVID-19)

Eurofins Bioanalytical Services launches Surrogate Virus Neutralizing antibody detection assays against the SARS-CoV-2 (COVID-19)
Share Article
Eurofins Bioanalytical Services, a member of Eurofins BioPharma Services, Laboratory Testing division, announces the launch of a Surrogate Virus Neutralization Test (sVNT) antibody assay against the SARS-CoV-2-virus. An alternative to conventional testing with a live virus, this assay is the first neutralizing antibody serology test authorized by the FDA as emergency use authorization (EUA). This innovative assay detects the presence of neutralizing/blocking antibodies against SARS-CoV-2 virus, that block the interaction between the receptor-binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor.

Related Keywords

United States ,Kristen Galkowski ,Eurofins Scientific Group ,Eurofins Bioanalytical Services ,Eurofins Biopharma Service ,Laboratory Testing ,Eurofins Biopharma Services ,Eurofins Central Laboratory ,Euronext Paris Stock Exchange ,Bioanalytical Services ,Surrogate Virus Neutralization Test ,Biopharma Service ,Eurofins Scientific ,Press Release ,ஒன்றுபட்டது மாநிலங்களில் ,ஆய்வகம் சோதனை ,உயிர் பகுப்பாய்வு சேவைகள் ,ப்ரெஸ் வெளியீடு ,